Lyra Therapeutics (LYRA) Fundamental Analysis: Revenue, Earnings & Valuation

6.67 / 10

Outperform

Fundamental analysis rates LYRA as Outperform with a 6.7/10 score. Strong interest coverage (15.6) and reasonable cost of sales (70.4%) support the view, yet negative ROE (-605%), annualized ROE (-806%) and a -70% YoY revenue drop raise concerns.

Analysis Checks(2/10)

Annualized return on equity (%)

Value-806.24

Score0/3

Weight-104.80%

1M Return-5.24%

Total operating revenue (YoY growth rate %)

Value-70.49

Score1/3

Weight-8.57%

1M Return-0.37%

Days sales outstanding

Value72.31

Score1/3

Weight-25.66%

1M Return-1.10%

Inventory turnover ratio

Value47.60

Score1/3

Weight-28.03%

1M Return-1.22%

PB-ROE

Value8.80

Score1/3

Weight109.90%

1M Return3.91%

Income tax / Total profit (%)

Value-0.04

Score1/3

Weight-21.65%

1M Return-0.91%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.63

Score2/3

Weight-13.49%

1M Return-0.56%

Cost of sales ratio (%)

Value70.36

Score2/3

Weight-13.42%

1M Return-0.58%

ROE (%)

Value-604.68

Score0/3

Weight-104.80%

1M Return-5.24%

Asset-MV

Value-0.49

Score1/3

Weight310.52%

1M Return9.60%

Is LYRA fundamentally strong?

LYRA scores 6.67/10 on fundamentals and holds a Discounted valuation at present. Backed by its -604.68% ROE, -5491.17% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 69.24% earnings growth, these metrics solidify its Outperform investment rating.

LYRA(Delisted)

Analysis Checks(2/10)